Introduction {#jbm410050-sec-0002}
============

Human bone marrow‐derived skeletal (also known as stromal or mesenchymal stem cells; hMSC) are multipotent adult stem cells. They are present in the bone marrow stroma and capable of self‐renewal and multi‐lineage differentiation into mesoderm‐type cells such as osteoblasts, adipocytes, and chondrocytes.[1](#jbm410050-bib-0001){ref-type="ref"}, [2](#jbm410050-bib-0002){ref-type="ref"} In addition, hMSC exhibit immune‐modulatory and regeneration‐enhancing characteristics based on secretion of a large number of molecules.[3](#jbm410050-bib-0003){ref-type="ref"} These qualities have encouraged clinical testing of hMSC for the enhancement of tissue regeneration after injury. As reviewed previously,[4](#jbm410050-bib-0004){ref-type="ref"} hMSC have been examined for their potential use in repair of bone defect and cartilage defects, enhancing tissue regeneration in ischemic heart disease, after acute renal injury as well as for treatment of steroid‐resistant graft versus host disease.

One of the major challenges of cellular therapeutics is how to generate large numbers of normal cells, through enhancing cell proliferation, while maintaining their biological and differentiation responses. Normal diploid cells, including hMSCs, exhibit a replicative senescence phenotype when cultured in vitro with an associated impairment of cellular functions.[5](#jbm410050-bib-0005){ref-type="ref"}, [6](#jbm410050-bib-0006){ref-type="ref"} Because the main mechanisms leading to in vitro replicative senescence is telomere shortening, caused by the absence of telomerase activity,[7](#jbm410050-bib-0007){ref-type="ref"} cellular telomerization has been suggested as an approach to generate cells suitable for therapies, eg, tissue engineering.[8](#jbm410050-bib-0008){ref-type="ref"} We have previously reported the generation and characterization of telomerized hMSC, which we termed hMSC‐TERT, and reported that telomerization abolished replicative senescence and not only maintained but enhanced bone formation capacity of the cells when implanted subcutaneously in immune‐deficient mice.[9](#jbm410050-bib-0009){ref-type="ref"} Other investigators corroborated these findings[10](#jbm410050-bib-0010){ref-type="ref"}, [11](#jbm410050-bib-0011){ref-type="ref"}, [12](#jbm410050-bib-0012){ref-type="ref"}, [13](#jbm410050-bib-0013){ref-type="ref"}, [14](#jbm410050-bib-0014){ref-type="ref"}, [15](#jbm410050-bib-0015){ref-type="ref"} (see summary of the telomerized cell lines in Table [1](#jbm410050-tbl-0001){ref-type="table"}). Telomerized hMSC are also good cellular models for primary hMSC because of their stable phenotype and are thus suitable for proteomic and genomic studies requiring the use of a large number of cells.[16](#jbm410050-bib-0016){ref-type="ref"}, [17](#jbm410050-bib-0017){ref-type="ref"}, [18](#jbm410050-bib-0018){ref-type="ref"} Conversely, telomerization may change the biology of hMSCs and may affect their relevance as a representative model for primary hMSC. To help understand this, global molecular phenotyping techniques such as DNA microarrays can be used. This method has been applied to the unbiased classification of cancer subtypes, as described in the landmark study by Golub and colleagues,[19](#jbm410050-bib-0019){ref-type="ref"} but it has not been widely used within the hMSC field. Thus, we performed molecular phenotyping using microarrays to compare primary hMSC and telomerized hMSC‐TERT cells that have previously been created in our group[9](#jbm410050-bib-0009){ref-type="ref"} and have been utilized in many studies by us and by others (more than 100 studies to date). We investigated the molecular pathways associated with the enhanced biological functions of telomerized hMSC and sought to clarify the relevance of these cells as cell models for primary hMSC. We investigated molecular phenotype by examining a set of osteoblast (OB) gene markers that are differentiation stage‐specific,[20](#jbm410050-bib-0020){ref-type="ref"} along with genes for cell surface markers, transcription factors, immune molecules, and signaling pathways.

###### 

Summary of Studies Investigating Immortalization of hMSC

  Source of MSC               Reference               Method                                                                                 Extended life span                                                                          Differentiation capacity (OB/AD/CC or other lineages)                                                                                      In vivo implantation                                                                                                   Tumorigenicity in vivo/in vitro
  --------------------------- ----------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Adipocytes                  Balducci et al., 2014   Adipose‐derived stem cells (hASCs) transduced with hTERT and SV‐40/HPV E6/E7           hASCs‐TS and hASCs‐TE cultured for 1 year with a population doubling level up to 100        Immortalized hASC‐TS but not hASC‐TE significantly reduced differentiation potential in OB and AD lineage                                  n/a                                                                                                                    hASC‐TERT did not show tumorigenic properties in vitro
  Bone marrow                 Skarn et al., 2014      Telomerization of BM‐MSC to form iMSC3\# cell line                                     Maintained in long‐term culture (155 population doublings)                                  iMSC\#3 maintained their capacity to differentiate into OB, AD, and CC lineages                                                            n/a                                                                                                                    iMSC\#3 had a normal karyotype; no tumor formation after 6 months of implantation of iMSC\#3 in mice
  Bone marrow                 Dai et al., 2017        hMSCs transfected with hTERT and CTLA4Ig                                               hTERT‐MSC and hTERT‐CTLAIg hMSCs showed extended life span in culture compared with hMSC    hTERT‐CTLAIg hMSCs retained OB differentiation capacity                                                                                    hTERT‐CTLA4Ig hMSCs formed bone (in vivo) when transplanted in rat                                                     hTERT‐CTA4Ig hMSCs did not form tumors after in vivo transplantation
  Bone marrow                 Piper et al., 2012      Inducible Tet‐On gene expression system to create immortalized hMSCs (i‐hTERT hMSCs)   i‐hTERT hMSCs able to proliferate significantly longer than primary hMSCs                   i‐hTERT hMSCs retain multipotentiality (OB, AD, CC) in vitro                                                                               n/a                                                                                                                    This cell line allows inducible expression of telomerase, therefore avoiding tumor formation
  Bone marrow                 Tsai et al., 2010       Ectopic overexpression hMSCs with HPV 16 E6E7 and hTERT                                Telomerized cells overcome senescence and could be passaged over 100 population doublings   hMSC‐HPV‐TERT had enhanced differentiation potential (OB and neural lineages); maintained differentation potential in CC and AD lineages   n/a                                                                                                                    n/a
  Fetal porcine pancreas      Cao et al., 2011        Transfected MSC with hTERT, resulting in immortalized cell line, iPMSCs                The iPMSCs have been cultured for more than 80 passages                                     Retain capacity for differentiation into neurons, cardiomyocytes, germ cells, and islet‐like cells                                         Transplantation of iPMSCs to diabetic mice may have the potential to mimic the normal physiological insulin response   iPMSCs were transplanted into mice; no tumors were observed for up to 2 months after injection
  Amniotic cells/adipocytes   Wolbank et al., 2009    Immortalized by ectopic expression of hTERT                                            Telomerized MSC expanded to at least PD60 with no signs of growth retardation               Similar or enhanced differentiation potential to OB and AD lineage compared with primary cells                                             n/a                                                                                                                    Telomerized MSCs showed a normal karyotype
  Bone marrow                 Huang et al., 2008      hMSCs transduced with exogenous hTERT (hTERT‐hMSCs                                     hTERT‐MSC cultured for 290 population doublings                                             hTERT‐MSCs maintained ability to differentiate into AD, CC, and OB                                                                         n/a                                                                                                                    hTERT‐MSCs were non‐tumorigenic in vivo; karyotype analysis of hTERT‐MSCs were normal
  Bone marrow                 Liu et al., 2013        MSCs immortalized using p53 and hTERT                                                  P53‐hTERT‐MSC maintained primary MSC morphology after 1 year of continuous culture          P53‐hTERT‐MSC retained differentiation potential for AD, CC, and OB                                                                        n/a                                                                                                                    In vivo transplantation of immortalized MSCs showed no tumor at 12 weeks
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Materials and Methods {#jbm410050-sec-0003}
=====================

Cell culture {#jbm410050-sec-0004}
------------

hMSC‐TERT cells were created as described previously, with hMSC obtained from a healthy 30‐year‐old male donor.[9](#jbm410050-bib-0009){ref-type="ref"} The cells exhibit all typical characteristics of hMSC.[9](#jbm410050-bib-0009){ref-type="ref"} The passage number for the hMSC‐TERT cells was p38 and population doubling level (PDL) 80. At this PDL, the cells exhibited a "stemness" phenotype in an in vivo heterotopic bone formation assay.[21](#jbm410050-bib-0021){ref-type="ref"} hMSC‐TERT cells were cultured in minimal essential media (MEM, Invitrogen, Carlsbad, CA, USA) with 10% v/v fetal bovine serum (FBS, PAA, Pasching, Austria).

Primary hMSC were derived from bone marrow aspirates taken from the iliac crest of healthy donors between the ages of 20 and 30 years. Both oral and written consent was obtained from each participant, and the project was approved by the regional Scientific Ethical Committee. Isolation of bone marrow mononuclear cells was performed in heparinized MEM using low‐density gradient centrifugation and Lymphoprep (Medinor, Bronby, Denmark).[22](#jbm410050-bib-0022){ref-type="ref"} hMSC were obtained through plastic adherence and cultured and expanded in MEM supplemented with 10% v/v FBS (PAA) and penicillin/streptomycin (Invitrogen) at a seeding density of 12.5 × 10^3^ cells per cm^2^.

Flow cytometry analysis {#jbm410050-sec-0005}
-----------------------

Flow cytometry (FACS) analysis of cell surface markers on hMSC‐TERT and primary hMSC was performed as described in Harkness and colleagues.[21](#jbm410050-bib-0021){ref-type="ref"} The preconjugated markers examined were CD44‐PE, CD63‐FITC, CD73‐PE, CD90‐PE, CD105‐PE, CD146‐PE, and CD166‐PE (all BD Pharmingen, San Diego, CA, USA). In brief, subconfluent cells were single‐cell suspended in trypsin, washed twice in FACS buffer (PBS^2‐^, 0.5% BSA), before incubation for 30 minutes on ice with one of the antibodies. After two wash steps with FACS buffer, flow cytometry was performed using a Cell Lab Quanta SC‐MPL and analysis performed using Kaluza 1.1 (both Beckman Coulter, Brea, CA, USA).

Osteoblastic differentiation {#jbm410050-sec-0006}
----------------------------

hBSMC‐TERT and primary hMSC were plated at 20,000 cells per cm^2^ in osteoblastic induction medium (OIM) as previously reported.[21](#jbm410050-bib-0021){ref-type="ref"} In brief, MEM was supplemented with 10 mM β‐glycerolphosphate (Calbiochem, EMD Millipore, Billerica, MA, USA), 50 µg/ml L‐ascorbic acid‐2‐phosphate (Wako Chemicals, Richmond, VA, USA), 10 nM dexamethasone (Sigma‐Aldrich, St. Louis, MO, USA), and 10 nM calcitrol (LEO Pharma, Madison, NJ, USA) for a maximum of 15 days. Medium was replaced every 3 days.

Alkaline phosphatase (ALP) activity was measured at day 6 of OIM using Cell Titre Blue (Promega, Madison, WI, USA) to measure cell viability and p‐nitro phenyl phosphate (pNP) to measure ALP activity as previously described.[21](#jbm410050-bib-0021){ref-type="ref"} Absorbance was measured on a FLUOstar Omega plate reader (BMG LabTech, Cary, NC, USA) and ALP activity corrected for cell viability (*n* = 6).

Immune staining and morphological analysis {#jbm410050-sec-0007}
------------------------------------------

hBSMC‐TERT and primary hMSC cultured in OIM were stained for ALP and matrix mineralization (Alizarin red \[AZR\]) at day 15 of induction as previously described.[23](#jbm410050-bib-0023){ref-type="ref"} In addition, non‐induced cells (control) and cells undergoing OIM were trypsinized (at day 9) and seeded in 96‐well flat‐bottom NUNC dishes at a cell count of 5000/well. The following day, cells were fixed in 10% formalin before staining. Wells were blocked with 5% FBS in phosphate‐buffered saline (PBS^2+^) for 1 hour at room temperature (RT) before overnight incubation with the antibody (ALP \[R&D Systems, Minneapolis, MN, USA, or Larry Fischer); Runt related transcription factor \[RUNX2, Abcam, Cambridge, MA, USA\]). Wells were washed and incubated with an appropriate fluorescent secondary (Alexa Fluor, Life Technologies, Carlsbad, CA, USA) for 1 hour at RT, before counterstaining with 1 μg/mL 4\',6‐diamidino‐2‐phenylindole (DAPI) for 15 to 30 minutes at RT. Cells were imaged using an Operatta High Content Screening system (PerkinElmer, Waltham, MA, USA).

In vivo heterotopic bone formation {#jbm410050-sec-0008}
----------------------------------

hMSC‐TERT cells and primary hMSC (0.5 × 10^6^) were single‐cell suspended and combined with 40 mg hydroxyl‐apatite tricalcium phosphate as previously described.[24](#jbm410050-bib-0024){ref-type="ref"} The cells were incubated overnight in hydroxyapatite‐tricalcium phosphate (HA/TCP) before implantation into the dorsolateral area of immune‐compromised mice (NOD.CB17‐Prkdcscid/J) for 8 weeks. After retrieval, implants were fixed overnight in 4% formalin and washed in PBS before decalcification in formic acid for 3 to 5 days. After embedding in paraffin, sections were cut and stained with hematoxylin and eosin or human specific‐vimentin antibody (\#RM‐9120, Clone SP20; Thermo Fisher Scientific, Waltham, MA, USA).

RNA extraction {#jbm410050-sec-0009}
--------------

Total RNA was isolated using TRIzol (Invitrogen) as previously reported.[9](#jbm410050-bib-0009){ref-type="ref"} After initial extraction, samples were additionally eluted using a GenElute mammalian total RNA miniprep kit (Sigma‐Aldrich; according to manufacturer\'s instructions) to achieve high‐purity RNA.

Microarray data generation and analysis {#jbm410050-sec-0010}
---------------------------------------

Total RNA was isolated using the GeneMatrix Universal RNA Purification Kit (Cat. E 3598‐02, Roboklon, Berlin, Germany) and quality‐checked by Nanodrop analysis (Nanodrop Technologies, Wilmington, DE, USA). Four hundred nanograms of total RNA was used as input for generating biotin‐labeled cRNA (Ambion, Austin, TX, USA). cRNA samples were then hybridized onto Illumina human‐8 Bead‐Chips version 3. Hybridizations, washing, Cy3‐streptavidin staining, and scanning were performed on the Illumina BeadStation 500 platform (Illumina, San Diego, CA, USA), according to the manufacturer\'s instruction. hMSC‐TERT RNA samples were analyzed in biological triplicate, and there were 15 samples of primary hMSCs from different individuals. Expression data analysis was carried out using the BeadStudio software 3.0 (Illumina). Raw data were background‐subtracted and normalized using the rank invariant algorithm. Data were then imported into R (version 3.03)[25](#jbm410050-bib-0025){ref-type="ref"} and the BioConductor package "limma"[26](#jbm410050-bib-0026){ref-type="ref"} was used to test for differential expression. Probes that were considered as expressed (detection *p* \< 0.01) in at least 3 of the samples were retained for further analysis. Lists of chondrocyte and adipocyte gene markers used in expression analysis were obtained from R&D Systems (<https://www.rndsystems.com/research-area/adipogenesis-markers>; <https://www.rndsystems.com/research-area/chondrogenesis-markers>).

Functional enrichment analysis {#jbm410050-sec-0011}
------------------------------

The Database for Annotation, Visualization, and Integrated Discovery (DAVID) v6.7[27](#jbm410050-bib-0027){ref-type="ref"} was employed to determine the functional enrichment for sets of differentially expressed genes between hMSC‐TERT and primary hMSC. The filtered set of probes (20,929) identified as expressed in at least 3 samples was used as the background list. MetaCore (v6.20, from Thompson Reuters) was also used for functional enrichment analysis of differentially expressed genes between hMSC‐TERT and primary hMSC. A number of fold‐change thresholds were used to create four lists of differentially regulated genes between hMSC‐TERT and primary hMSC. Thresholds were set at log~2~ fold change of 0.5, 1, 1.5, and 2. All gene lists (summarized in Supplemental Table S1) were generated using an adjusted *p* value threshold of 0.05. Pathways were ranked from most to least significantly enriched for each gene list. The rank for pathways in common across the four gene lists were then summed to indicate which pathways are highly ranked for all gene lists.

Results {#jbm410050-sec-0012}
=======

hMSC‐TERT and primary hMSC exhibit a similar pattern of CD markers and form heterotopic bone in vivo {#jbm410050-sec-0013}
----------------------------------------------------------------------------------------------------

The cellular phenotype of hMSC‐TERT and primary hMSC was compared using FACS analysis of characteristic hMSC surface markers. As shown in Fig. [1](#jbm410050-fig-0001){ref-type="fig"} *A*, there was a similar percentage of positive cells for CD44, CD63, CD73, CD90, CD105, CD146, and CD166, between primary hMSC and hMSC‐TERT cells. Both cell populations were negative for CD14, which is a known marker for monocytes and macrophages.[28](#jbm410050-bib-0028){ref-type="ref"} Primary hMSC and hMSC‐TERT showed similar morphologies (Fig. [1](#jbm410050-fig-0001){ref-type="fig"} *B*). In addition, both differentiated readily to OB in vitro as evidenced by expression of OB markers ALP, BGLAP, and RUNX2, formation of mineralized matrix, and increased ALP activity (Fig. [1](#jbm410050-fig-0001){ref-type="fig"} *C--E*). hMSC‐TERT and primary hMSC formed heterotopic bone and bone marrow organ when implanted subcutaneously in immune‐deficient mice, corroborating their "stemness" (Fig. [1](#jbm410050-fig-0001){ref-type="fig"} *F*).

![Telomerized human bone marrow skeletal (stromal) stem cells (hMSC‐TERT) exhibit similar phenotype to primary hMSC. (*A*) FACS analysis of canonical CD surface markers expressed in primary hMSC versus hMSC‐TERT. Primary hMSC are indicated in blue, hMSC‐TERT in green, and isotype control in red. (*B*) Primary hMSC and hMSC‐TERT cells exhibit similar morphologies. Cells were stained with F‐actin (Phalloidin‐555) and hoechst. Scale bars = 100 μm. (*C*) Cellular staining for primary hMSC and hMSC‐TERT at day 10 post‐OB induction. For each cell type: nuclear stained DAPI (left); antibody to OB marker RUNX2, ALP, or BGLAP with a secondary FITC antibody (middle); overlayed images (right). Scale bars = 100 μm. (*D*) Alizarin red staining of mineralized matrix formation in primary hMSC and hMSC‐TERT at day 0 and day 15 post‐OB induction. (*E*) Alkaline phosphatase activity at day 6 post‐OB induction of primary hMSC and hMSC‐TERT cells. Data plotted as mean ± SD; *n* = 6 replicates (\*\*\*\**p* \< 0.001). (*F*) In vivo ectopic bone formation after subcutaneously implanted primary hMSC and hMSC‐TERT mixed with hydroxyapatite/tricalcium phosphate (HA/TCP) in immune‐deficient mice. Histological sections of implants with cells after 8 weeks of the implantation stained with H&E. A = adipocyte; S = sinusoid; B = bone; HA= hydroxyapatite. Scale bars = 100 μm.](JBM4-2-257-g001){#jbm410050-fig-0001}

hMSC‐TERT and primary hMSC show a similar global gene expression phenotype {#jbm410050-sec-0014}
--------------------------------------------------------------------------

We measured the overall similarity in gene expression between all primary hMSC and all hMSC‐TERT samples by correlating their global gene expression profiles from microarrays and performing principal components analysis (PCA). PCA shows the two cell types form discrete clusters, with more variability within primary hMSC than hMSC‐TERT cells (Fig. [2](#jbm410050-fig-0002){ref-type="fig"} *A*). For all expressed genes, the average Pearson\'s correlation coefficient (R^2^) was 0.95 (range 0.93--0.96), while the average R^2^ within primary hMSC samples was 0.98 (range 0.97--0.99) and the average R^2^ value within hMSC‐TERT samples was 0.99 (range 0.99--0.99) (Fig. [2](#jbm410050-fig-0002){ref-type="fig"} *B*, *C*). This indicates a very high similarity of global gene expression between the two cell types.

![Telomerized human bone marrow skeletal (stromal) stem cells (hMSC‐TERT) exhibit a similar molecular phenotype to primary hMSC. (*A*) Principal components analysis demonstrates that primary hMSC (*n* = 15, orange) samples cluster separately from hMSC‐TERT samples (*n* = 3, blue). (*B*) Scatterplot showing correlation and coefficient of determination (R[2](#jbm410050-bib-0002){ref-type="ref"} value) between global gene expression for all primary hMSC (*n* = 15) and all hMSC‐TERT (*n* = 3) samples. (*C*) Correlation heatmap for all primary hMSC and all hMSC‐TERT samples. The Pearson correlation between each sample is shown and colored according to score. (*D*) Proportional representation for three types of genes differentially regulated between primary hMSC and hMSC‐TERT. Orange proportion refers to genes that are significantly different in gene expression between the cell types, whereas blue refers to genes that are similar in gene expression between the cell types.](JBM4-2-257-g002){#jbm410050-fig-0002}

hMSC‐TERT and primary hMSC exhibit a similar CD marker gene expression phenotype {#jbm410050-sec-0015}
--------------------------------------------------------------------------------

We next focused on specific groups of genes that are relevant to hMSC biology. We first determined the similarity of expression for a set of CD surface markers, in hMSC‐TERT and primary hMSC. For this, we examined a set of 50 CD markers that were curated from a previous publication; these constitute the core CD marker signature of MSC.[29](#jbm410050-bib-0029){ref-type="ref"} All of the 50 CD markers were expressed in both cell types, consistent with our observations from FACS analysis of a smaller set of markers. There was also strong correlation of gene expression between the hMSC‐TERT and primary hMSC cells (all markers and fold changes are listed in Supplemental Table S2), where a total of 36/50 CD markers (72%) did not show any significant quantitative change in gene expression between hMSC‐TERT cells and primary hMSC (Fig. [2](#jbm410050-fig-0002){ref-type="fig"} *D*, Supplemental Table S2). Among the CD markers, 14/50 (28%) were differentially regulated in the hMSC‐TERT compared with primary hMSC (\>2 fold change \[FC\], *p* \< 0.05) (Fig. [2](#jbm410050-fig-0002){ref-type="fig"} *D*, Table [2](#jbm410050-tbl-0002){ref-type="table"}). The most dramatically downregulated cell surface markers were ICAM2 (−43.65 FC) and HLA‐DRA (−21.13 FC). Two other CD markers, THY1 (CD90) and CD44, showed significant differences in gene expression (details in Table [2](#jbm410050-tbl-0002){ref-type="table"}), but this result was not corroborated in our FACS analysis (Fig. [1](#jbm410050-fig-0001){ref-type="fig"} *A*). Functional enrichment of the 14 CD markers that show differential gene expression identified wound healing (*p* = 4.24 × 10^−4^) (CD44, CD9, COL3A1, ITGB3) and immune response (*p* = 1.7 × 10^−3^) (CD164, CD97, IL1R1, HLA‐DRA, TNFRSF1B) as functional processes associated with these markers.

###### 

CD and OB Markers Significantly Differentially Regulated Between hMSC‐TERT and Primary hMSC

  Gene symbol   Gene name                                                     Fold change   Adjusted *p* value
  ------------- ------------------------------------------------------------- ------------- --------------------
  CD markers                                                                                
  CD9           CD9                                                           7.13          3.67E‐03
  THY1          Thy‐1 cell surface antigen                                    3.65          1.71E‐03
  CD44          CD44                                                          2.56          9.20E‐03
  CD97          CD97                                                          2.35          7.57E‐03
  CD82          CD82                                                          2.18          4.18E‐04
  TNFRSF1B      Tumor necrosis factor receptor superfamily member 1B          −2.13         8.03E‐04
  COL3A1        Collagen type III                                             −2.48         2.10E‐02
  CD164         CD164                                                         −2.49         9.98E‐07
  IL1R1         Interleukin 1 receptor type 1                                 −2.92         4.88E‐02
  PVRL2         Nectin cell adhesion molecule 2                               −3.62         2.35E‐02
  CD109         CD109                                                         −7.36         6.47E‐07
  ITGB3         Integrin subunit beta 3                                       −9.03         6.89E‐06
  HLA‐DRA       Major histocompatibility complex, class II, DR alpha          −21.13        5.45E‐04
  ICAM2         Intercellular adhesion molecule 2                             --43.65       3.36E‐04
  OB markers                                                                                
  COL4A5        Collagen type IV alpha 5                                      317.56        4.78E‐06
  CD24          CD24                                                          57.30         2.91E‐06
  BMP4          Bone morphogenic protein 4                                    9.21          1.43E‐03
  ALPL          Alkaline phosphatase                                          7.58          3.57E‐02
  CLEC3B        C‐type lectin domain family 3 member B                        7.37          2.24E‐03
  MFAP5         Microfibrillar associated protein 5                           3.82          2.96E‐02
  SCARB1        Scavenger receptor class b member 1                           3.65          1.22E‐05
  OAS3          2\'‐5\'‐oligoadenylate synthetase 3                           3.16          4.76E‐02
  COL7A1        Collagen type VII alpha 1                                     3.04          1.30E‐05
  IFIT1         Interferon induced protein with tetratricopeptide repeats 1   2.89          1.46E‐02
  HSPG2         Heparan sulfate proteoglycan 2                                2.68          2.16E‐02
  ITGA7         Integrin subunit alpha 7                                      2.52          4.71E‐04
  OAS1          2\'‐5\'‐oligoadenylate synthetase 1                           2.38          1.08E‐03
  EPHA2         EPH receptor A2                                               2.22          8.47E‐03
  FBN2          Fibrillin 2                                                   2.22          2.06E‐02
  COL3A1        Collagen type III alpha 1                                     −2.48         2.10E‐02
  CTHRC1        Collagen triple helix repeat containing 1                     −2.52         6.55E‐04
  WWOX          WW domain containing oxidoreductase                           −2.55         1.26E‐02
  PDGFA         Platelet derived growth factor subunit A                      −2.63         1.36E‐02
  ICAM1         Intercellular adhesion molecule 1                             −2.88         1.41E‐05
  COL8A2        Collagen type VIII alpha 2                                    −3.09         3.56E‐02
  PLOD2         Procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 2            −3.32         6.80E‐06
  IGF2          Insulin like growth factor 2                                  −3.72         2.91E‐02
  POSTN         Periostin                                                     −3.79         6.95E‐05
  TGFB2         Transforming growth factor beta 2                             −5.01         1.55E‐02
  SGCD          Sarcoglycan delta                                             −6.17         1.33E‐02
  BST2          Bone marrow stromal cell antigen 2                            −6.37         8.69E‐07
  COL18A1       Collagen type XVIII alpha 1                                   −8.80         5.64E‐04
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hMSC‐TERT and primary hMSC share a similar pattern of osteoblastic gene expression phenotype {#jbm410050-sec-0016}
--------------------------------------------------------------------------------------------

The hMSC‐TERT and primary hMSC were next compared for expression of a set of 123 recently defined OB markers that reflect the differentiating osteoblastic phenotype.[20](#jbm410050-bib-0020){ref-type="ref"} All of the 123 OB markers were expressed in both hMSC‐TERT and primary hMSC and 95/123 (77%) of the markers showed no significant difference in expression between the two cell populations (Fig. [2](#jbm410050-fig-0002){ref-type="fig"} *D*). The remaining 28 (23%) OB markers were differentially regulated between primary hMSC and hMSC‐ TERT (\>2 FC or \<−2 FC, *p *\< 0.05). These 28 OB markers, their gene symbols, fold changes and *p* values are detailed in Table [2](#jbm410050-tbl-0002){ref-type="table"}. All OB markers and associated fold change and *p* values are listed in Supplemental Table S3.

hMSC‐TERT and primary hMSC were also compared in terms of their expression of adipocytic markers and chondrogenic markers. Of the 25 adipocyte markers that were compared (Supplemental Table S3), 12 (48%) were expressed in both hMSC‐TERT and primary hMSC and only 2 (8%) were significantly differentially expressed between the two cell types (\>2 FC or \<−2 FC, *p* \< 0.05). Twenty‐four chrondrocyte markers were compared between hMSC‐TERT and primary hMSC, 12 (50%) were expressed in both cell types, and 3 (12.5%) were significantly differentially expressed between cell types (\>2 FC or \<−2 FC, *p *\< 0.05) (Supplemental Table S3). These data represent baseline measurements and may thus reflect differences in cellular heterogeneity between hMSC‐TERT and primary hMSCs.

To understand the possible mechanisms associated with this, we compared gene expression of all human transcription factors (TFs) in hMSC‐TERT and primary hMSC. These were from a curated list of 1412 human TFs.[30](#jbm410050-bib-0030){ref-type="ref"} We found that 722 TFs were significantly expressed in both primary hMSC and hMSC‐TERT (Illumina detection *p *\< 0.01) and that 587 of these 722 (81%) were not significantly different in gene expression between the two cell populations (Fig. [2](#jbm410050-fig-0002){ref-type="fig"} *D*). The remaining 135 (19%) TFs were significantly differentially regulated in hMSC‐TERT relative to primary hMSC (\>2 FC or \<−2 FC, *p *\< 0.05, Supplemental Table S4). The set of 722 TFs expressed in both primary hMSC and hMSC‐TERT is listed in Supplemental Table S5, including associated fold changes and *p* values. Biological processes that were significantly enriched in this set of 135 differentially regulated TFs included somatic stem cell population maintenance (*p *\< 0.001) and the development‐associated processes embryonic digestive tract morphogenesis (*p* \< 0.02) and skeletal muscle cell differentiation (*p *\< 0.04). Given that we were analyzing a set of transcription factors, the most highly enriched biological processes were those relating to transcriptional regulation (*p *\< 1.72 × 10^−50^).

Telomerization enhances canonical functions of hMSC {#jbm410050-sec-0017}
---------------------------------------------------

Because telomerization has been associated with enhanced OB differentiation and bone formation, we investigated the possible molecular mechanisms associated with this. We employed the Metacore pathway analysis tool to assess biological processes and pathways regulated differently because of telomerization, and we included all differentially expressed genes through use of four fold‐change thresholds. Pathways that ranked highest in all four gene lists included the cell cycle, namely: "The metaphase checkpoint" (sum of ranks = 9); "Role of APC in cell cycle regulation" (sum of ranks = 22); "Spindle assembly and chromosome separation" (sum of ranks = 41); "Initiation of mitosis" (sum of ranks = 42); and "Role of Nek in cell cycle regulation" (sum of ranks = 95). An increase in cell cycle pathways aligns with our functional studies showing that hMSC‐TERT cells proliferate faster than primary hMSC.[9](#jbm410050-bib-0009){ref-type="ref"} Other high‐ranking pathways common to all four gene lists were "SCAP/SREBP Transcriptional control of cholesterol biosynthesis" (sum of ranks = 10) and "Cytoskeleton remodeling keratin filaments" (sum of ranks = 19), both of which are also consistent with faster cell proliferation.

hMSC are known to play key roles in enhancing repair of damaged tissues, mediated through secretion of a large number of growth factors and cytokines[31](#jbm410050-bib-0031){ref-type="ref"} that modulate the immune response.[31](#jbm410050-bib-0031){ref-type="ref"} Comparing growth factors and immune modulatory gene profiles commonly showed similar patterns between the two cell types. However, we also observed some differences. Some growth factors showed significant change (\>2 FC or \<−2 FC, *p* \< 0.05) in gene expression in hMSC‐TERT compared with primary hMSC cells (Table [3](#jbm410050-tbl-0003){ref-type="table"}). Epidermal growth factor, platelet‐derived growth factor A, fibroblast growth factor 7, and transforming growth factor were downregulated, whereas fibroblast growth factor 5 was upregulated. By contrast, vascular endothelial growth factor, hepatocyte growth factor, insulin‐like growth factor, angiopoietin 1, erythropoetin, glial cell derived neurotrophic factor, C‐X‐C motif chemokine ligand 12, and interleukin 18 did not show significant differences between the cell types. With respect to immunomodulatory factors, we identified 11 genes that exhibited significant expression difference between hMSC‐TERT and primary hMSC cells (\>2 FC or \<−2 FC, *p* \< 0.05) (Table [3](#jbm410050-tbl-0003){ref-type="table"}). Indoleamine was downregulated as was TNFα‐stimulated gene/protein 6. Semaphorin A was upregulated, as was interleukin 10, interleukin 12A, and interleukin 1 receptor type 1. Other genes, critical for hMSC‐mediated immunosuppression, did not show significant differences in expression between the two cell types. These included chemokine ligand 2, B7‐H4, human leukocyte antigen G, leukemia inhibitory factor, galectins, heme oxygenase‐1, interleukin 6 prostaglandin E2, programmed cell death 1 ligand 1 /2, and Fas ligand.

###### 

Immune Molecules Significantly Differentially Regulated Between hMSC‐TERT and Primary hMSC

  Gene name                          Gene symbol   Fold change   Adjusted *p* value
  ---------------------------------- ------------- ------------- --------------------
  Growth factors                                                 
  Fibroblast growth factor 5         FGF           8.05          4.5 × 10^−5^
  Transforming growth factor         TGFB2         −2.32         1.50E‐02
  platelet‐derived growth factor A   PDGFA         −2.63         1.30E‐02
  Epidermal growth factor            EGF           −3.98         1.00E‐03
  Fibroblast growth factor 7         KGF           −6.64         6.00E‐03
  Immunomodulatory factors                                       
  Semaphorin A                       SEMA3A        4.28          1.48 × 10^−6^
  Interleukin 12A                    IL12A         3.51          1.00E‐02
  Interleukin 1 receptor type 1      IL1R1         2.91          4.80E‐02
  Interleukin 10                     IL10          2.15          3.2 × 10^−5^
  Indoleamine                        IDO           −3.96         2.00E‐02
  TNFα‐stimulated gene/protein 6     TSG           −4.01         5.00E‐03
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Telomerization is associated with upregulation of cancer‐associated antigens {#jbm410050-sec-0018}
----------------------------------------------------------------------------

As noted above, there was high correlation of overall gene expression between hMSC‐TERT and primary hMSC cells. However, there were also some significant differences in gene expression; the most up‐ and downregulated genes in hMSC‐TERT relative to primary hMSC are described in Table [4](#jbm410050-tbl-0004){ref-type="table"}. The top 10 most upregulated genes were TERT, MAGEC2, PAGE5, COL4A5, PAGE2, FAM133A, TM4SF1, CSAG1, PAGE2B, and FOLR3. The top 10 most downregulated genes were BEX1, SMOC1, TF, KCNMB1, TSPAN18, NDN, DPYSL4, SOX11, BEND5, and C20orf186.

###### 

Highest Significantly Up and Downregulated Genes in hMSC‐TERT Relative to Primary hMSC

  Gene symbol   Gene name                                                                   Fold change   Adjusted *p* value
  ------------- --------------------------------------------------------------------------- ------------- --------------------
  TERT          Telomerase reverse transcriptase                                            844.10        2.84E‐11
  MAGEC2        MAGE family member C2                                                       831.43        1.59E‐09
  PAGE5         PAGE family member 5                                                        535.43        4.06E‐07
  COL4A5        Collagen type IV alpha 5                                                    317.56        4.78E‐06
  PAGE2         PAGE family member 2                                                        227.47        1.78E‐04
  FAM133A       Family with sequence similarity 133 member A                                215.53        1.53E‐07
  TM4SF4        Transmembrane 4 L six family member 4                                       203.13        2.86E‐04
  CSAG1         Chondrosarcoma associated gene 1                                            146.09        9.37E‐15
  PAGE2B        PAGE family member 2B                                                       114.60        1.11E‐06
  FOLR3         Folate receptor 3 (gamma)                                                   92.75         2.39E‐04
  C20orf186     BPI fold containing family B member 4                                       −104.96       2.49E‐02
  BEND5         BEN domain containing 5                                                     −118.17       1.19E‐06
  SOX11         SRY‐box 11                                                                  −130.27       2.84E‐06
  DPYSL4        Dihydropyrimidinase‐like 4                                                  −138.30       4.16E‐15
  NDN           Necdin                                                                      −177.87       1.27E‐16
  TSPAN18       Tetraspanin 18                                                              −212.73       1.55E‐12
  KCNMB1        Potassium calcium‐activated channel subfamily M regulatory beta subunit 1   −243.54       3.91E‐08
  TF            Transferrin                                                                 −251.01       3.00E‐04
  SMOC1         SPARC related modular calcium binding 1                                     −280.03       4.76E‐04
  BEX1          Brain expressed X‐linked 1                                                  −1404.44      4.03E‐07
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Interestingly, 4 of the top 10 most upregulated genes in hMSC‐TERT, compared with primary hMSC, were MAGE or PAGE cancer‐associated antigens.[32](#jbm410050-bib-0032){ref-type="ref"} Specifically, these were MAGEC2, PAGE5, PAGE2, and PAGE2B (Supplemental Table S6). All these genes show negligible expression levels in primary hMSC but high levels of expression in hMSC‐TERT cells, leading to up to 1800‐fold expression changes (Supplemental Fig. S1). Our group has previously reported the expression of GAGE and MAGE cancer antigens in tumorigenic telomerized hMSC‐TERT20 cells.[33](#jbm410050-bib-0033){ref-type="ref"} However, the hMSC‐TERT employed in the current study are not tumorigenic, suggesting that telomerization per se may be associated with upregulation of this gene set, forming a possible "telomerization signature."

Discussion {#jbm410050-sec-0019}
==========

In this study, we compared telomerized hMSC with primary hMSC employing a set of cell surface molecules, transcription factors and genes associated with intracellular signalling and demonstrated that telomerization preserved the molecular phenotype and maintained biological characteristics of hMSC.

Both hMSC‐TERT cells and primary hMSC shared CD markers described as the minimal criteria for defining multipotent stromal (mesenchymal) cells.[34](#jbm410050-bib-0034){ref-type="ref"} These results are similar to a number of previous studies. hMSC isolated using an anti‐stro‐1 antibody, which is known to enrich for multipotent hMSC,[35](#jbm410050-bib-0035){ref-type="ref"} were compared to hMSC‐TERT and reported that among 35 CD markers examined, 31 showed no significant quantitative change in expression. Similarly, Skarn and colleagues[14](#jbm410050-bib-0014){ref-type="ref"} showed that the hMSC line (iMSC\#3) showed no difference in cell surface markers compared with the primary hMSC.

In addition to similarities in CD marker expression, both cell types were capable of forming heterotopic bone and bone marrow organ in vivo. This has been described as the most important "stemness" criteria for hMSC. Thus, at a functional level, telomerization maintained "stemness" characteristics. Our observation corroborates results reported by Dai and colleagues,[10](#jbm410050-bib-0010){ref-type="ref"} who also showed that hMSC transfected with hTERT‐CTLA4Ig formed bone in vivo.

We observed similar differentiation capacity in vitro between telomerized hMSC and primary hMSC. Whereas Dale and colleagues[36](#jbm410050-bib-0036){ref-type="ref"} showed that hTERT transduction of HMSCs affected differentiation potential of the cells to varying degrees, several published studies reported that telomerization in a number of stromal cell populations maintain biological characteristics of the cells. Balducci and colleagues[37](#jbm410050-bib-0037){ref-type="ref"} generated an adipose‐derived stromal cell line using transfection with hTERT and sv40 or HPV E6/E7 and the cells retained osteogenic and adipogenic differentiation potential. Wolbank and colleagues[38](#jbm410050-bib-0038){ref-type="ref"} established and characterized human adipose and amnion‐derived MSC lines, using ectopic expression of hTERT, and again the cells had in addition to unaltered constellation of CD markers, similar or enhanced differentiation potential during long‐term culture (up to 87 population doublings). Also, an immortalized MSC cell line (iPMSC) derived from fetal porcine pancreas[39](#jbm410050-bib-0039){ref-type="ref"} maintained their biological characteristics. We summarize these data in Table [1](#jbm410050-tbl-0001){ref-type="table"}.

We also observed a high degree of consistency in the expression of OB, chrondrocyte, and adipocyte marker genes between the primary hMSC and hMSC‐TERT cells. A small proportion of genes relevant to the biological functions of hMSC showed significant upregulation. For example, COL4A5 was upregulated by 317.45 FC in hMSC‐TERT relative to primary hMSC. Type IV collagens are structural proteins making up the foundation for all basement membranes. These collagens form heterotrimers and interact with laminins, proteoglycans, and entactin to form an extracellular protein network.[40](#jbm410050-bib-0040){ref-type="ref"} Increased levels of COL4A5 in hMSC‐TERT may thus be related to improved in vivo bone formation function of the cells.

In addition to the extensive similarities in molecular phenotype between hMSC‐TERT and primary hMSC, we observed some differences in transcription factor and cell surface marker gene expression. Most of the differences were associated with increased cell proliferation in hMSC‐TERT, suggesting that the observed enhanced biological functions in hMSC‐TERT can be explained mainly by the hTERT‐mediated anti‐replicative senescence mechanisms. The most dramatically downregulated cell surface markers upon telomerization were ICAM2 and HLA‐DRA. Both ICAM2 and HLA‐DRA are involved in an antitumor immune response.[41](#jbm410050-bib-0041){ref-type="ref"}, [42](#jbm410050-bib-0042){ref-type="ref"} HLA‐DRA is a MHC class II protein and presents antigens to CD4+ T cells as part of the cellular immune response. This interaction results in T‐cell activation and a strong immune response.[43](#jbm410050-bib-0043){ref-type="ref"} ICAM2 is a glycoprotein that mediates adhesive interactions with T cells and has also been shown to mediate antitumor immune response in human pancreatic carcinogenesis.[42](#jbm410050-bib-0042){ref-type="ref"} These effects may be caused by telomerization‐associated downregulation of antitumor response genes, which is relevant to the role of telomerization in cancer biology.[44](#jbm410050-bib-0044){ref-type="ref"}

A total of 19% of transcription factors analyzed showed significant change between hMSC‐TERT and primary hMSC. Two transcription factors that showed dramatic change were SOX11 (−130 FC) and TFAP2A (29 FC). SOX11 is a transcriptional regulator involved in embryonic neurogenesis and tissue modeling.[45](#jbm410050-bib-0045){ref-type="ref"} De novo mutations in SOX11 have been shown to cause Coffin‐Siris, a syndrome that includes skeletal dysmorphism in humans,[46](#jbm410050-bib-0046){ref-type="ref"} demonstrating its importance for skeletogenesis. Recently, Gadi and colleagues[47](#jbm410050-bib-0047){ref-type="ref"} showed that SOX11C‐deficient mouse osteoblastic cell line (MC3T3‐E1) exhibit reduced cell proliferation and a significant delay in OB differentiation. TFAP2 is a member of the AP‐2 family of transcription factors, which play important roles in apoptosis, migration, and differentiation.[48](#jbm410050-bib-0048){ref-type="ref"} Mutations in TFAP2A lead to branchio‐oculo‐facial syndrome, which is a cleft palate‐craniofacial disorder.[49](#jbm410050-bib-0049){ref-type="ref"} TFAP2 knockout mice have severe skeletal defects and abnormalities of face and limbs, and studies demonstrate the main function of TFAP2 is suppression of terminal differentiation during embryonic development.[50](#jbm410050-bib-0050){ref-type="ref"}, [51](#jbm410050-bib-0051){ref-type="ref"} This implicates TFAP2 as playing a role in skeletal biology.

We have also observed upregulation of numerous cancer/testis antigens in the PAGE and MAGE gene family in hMSC‐TERT relative to primary hMSC. Increase in cancer antigen families in telomerized hMSC have been reported, including previous work from our group, which studied the tumorigenic hMSC‐TERT20.[33](#jbm410050-bib-0033){ref-type="ref"}, [52](#jbm410050-bib-0052){ref-type="ref"} In another study of telomerized hMSC,[14](#jbm410050-bib-0014){ref-type="ref"} similar changes were observed. These cancer antigen gene functions are poorly understood, although they are frequently expressed in tumor or embryonic tissues but not in somatic tissues (as reviewed in Simpson and colleagues[53](#jbm410050-bib-0053){ref-type="ref"}). Knockdown of PAGE5 in melanoma cells resulted in a decrease in cell survival when cells were exposed to apoptosis‐inducing cisplatin. PAGE5 has also been shown to negatively regulate the expression of apoptotic genes and promote the survival of melanoma cells via suppression of apoptosis.[54](#jbm410050-bib-0054){ref-type="ref"} The MAGE antigen MAGE2C, which was upregulated in hMSC‐TERT relative to primary hMSC, promotes both cell proliferation and viability of mast cells.[55](#jbm410050-bib-0055){ref-type="ref"} Recently, CRISPR/Cas9 MAGEC2 knockout melanoma cells have been shown to have increased TNFα‐induced apoptosis.[56](#jbm410050-bib-0056){ref-type="ref"} Collectively, MAGE genes have been shown to repress p53 transactivation and apoptosis and regulate cell cycle progression (as reviewed in Sang and colleagues[57](#jbm410050-bib-0057){ref-type="ref"}). Telomerization increases the proliferative life span of the hMSC‐TERT cells, and this may be enhanced by cancer antigen‐mediated suppression of apoptosis and regulation of cell cycle progression. These cancer antigen genes may represent a common gene expression signature induced by telomerization.

In summary, we have shown that the telomerized hMSC and primary hMSC are highly similar in both their molecular and cellular phenotypes, suggesting their suitability as a model for primary hMSC. In addition, the observed enhancement of hMSC biological function after telomerization may be mediated by increased levels of cell proliferation.
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